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Multiple myeloma is a malignancy of B-cells that is characterized by the clonal expansion 
and accumulation of malignant plasma cells in the bone marrow. This disease remains 
incurable, and a median survival of 3-5 years has been reported with the use of current 
treatments. Viral-based therapies offer promising alternatives or possible integration with 
current therapeutic regimens. Among several gene therapy vectors and oncolytic agents, 
adenovirus has emerged as a promising agent, and it is already being used for the treatment 
of solid tumors in humans. The main concern with the clinical use of this vector has been 
its high immunogenicity; adenovirus is often able to induce a strong immune response 
in the host. Furthermore, new limitations in the efficacy of this therapy, intrinsic to the 
nature of tumor cells, have been recently observed. For example, our group showed a 
strong antiviral phenotype in vitro and in vivo in a subset of tumors, shedding new insights 
that may explain the partial failure of clinical trials based on this promising new therapy. 
In this review, we describe novel therapeutic approaches that implement viral-based treat-
ments in hematological malignancies and address the novelty as well as the possible limi-
tations of these new therapies, especially in the context of the use of adenoviral vectors 
for treating multiple myeloma.
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INTRODUCTION
Multiple myeloma (MM) is the most common primary 
bone cancer, representing 10% of all hematological malig-
nancies and 1-2% of all cancer-related deaths [1], and occurs 
when malignant of B-cells progressively infiltrate the bone 
marrow and produce immunoglobulin after clonal expansion 
[2]. Conventional therapeutic protocols include chemo-
therapy with bone marrow transplantation and drug treat-
ment involving combinations of melphalan, vincristine, car-
mustine (bischloroethylnitrosourea), cyclophosphamide, 
doxorubicin (Adriamycin), thalidomide, and prednisone and 
dexamethasone [3, 4]. These agents, used as monotherapies 
or in combination, have significantly improved MM out-
comes, but long-term tolerance, graft-versus-host disease, 
and toxicities associated with some of these drugs represent 
great limitations [5]. The median survival is still only 3-5 
years, and cases of relapse are frequent [6]. New drugs, such 
as bortezomib (Velcade) and lenalidomide (Revlimid), have 
recently been introduced as novel and more-curative 
therapies. However, like with conventional treatments, 
long-term tolerance and toxicities associated with these drugs 
are major limitations [5]. Therefore, new therapies are defi-
nitely needed.
Historically, remission of hematological malignancies, 
such as Burkitt’s lymphoma and Hodgkin’s disease, has been 
shown to be induced by clinical infection with the measles 
virus (MV) [7]. This finding paved the way for 2 major 
therapeutic strategies: The first is based on the use of viruses 
as oncolytic agents (http://www.hindawi.com/journals/av/ 
2012/186512/), since oncolytic viruses preferentially repli-
cate in tumor cells by taking advantage of cancer-specific 
cellular changes [8]. This specificity is usually improved by 
deleting the E1A viral gene that is required for replication 
[9]. The second strategy, instead, uses different categories 
of viruses as possible vectors to deliver genes inside human 
tumor cells. Among the viruses used for viral therapy of 
tumors, 4 RNA viruses (MV, vesicular stomatitis virus, re-
ovirus, and CVA21 [coxsackievirus A21]) and 2 DNA viruses 
(adenovirus and VV [vaccinia virus]) have been studied, with 
the goal of finding a translational application for the treat-Korean J Hematol 2011;46:229-38.
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ment of multiple myeloma [10].
The adenovirus vectors have been the most commonly 
used vectors in human cancer treatment, especially for cancer 
gene therapy strategies based on intratumoral injection 
(Supplementary Table 1) [11]. Therefore, the first part of 
this review focuses on adenovirus and adenovirus-derived 
vectors and describes the state-of-the-art application of these 
viruses as oncolytic or gene therapy vectors and the potential 
therapeutic use of adenovirus vectors for the cure of MM. 
In the second part of this review, we discuss a significant 
new cancer antiviral phenotype described by our group that 
is shared by solid and hematologic malignancies and that 
may prove to be one of the causes of the partial failure 
of viral-based therapeutic trials.
ADENOVIRUS AS A VECTOR FOR ONCOLYTIC 
THERAPY IN MULTIPLE MYELOMA
Adenoviruses are nonenveloped, dsDNA viruses that, in 
nature, infect cells by binding the fibrous knob of the cox-
sackie and adenovirus receptor (CAR) expressed on the sur-
face of target cells [11]. As vectors for oncolytic therapies, 
these viruses have many advantages over other vectors, in-
cluding the capability of transducing and replicating in divid-
ing as well as non-dividing cells, the ease of manipulation, 
and a naturally lytic replication cycle, highlighting the use-
fulness of these viruses for in vitro production and in vivo 
curative effects (viruses naturally increase the “dosage” while 
replicating) [12]. As vectors, adenoviruses have a relatively 
good safety profile and result in a greater survival rate than 
other therapeutic vectors. Successful treatment of a variety 
of tumors using adenoviruses has been demonstrated, and 
they are highly efficient at in vivo gene delivery [11]. Since 
1993, more than 300 clinical trials based on adenoviral vectors 
have been performed [11], with promising outcomes 
(Supplementary Table 1 and http://www.clinicaltrials.gov/). 
Although the first clinical results of trials based on adenovirus 
as an oncolytic therapeutic agent have been promising, show-
ing clinical safety and the feasibility of the approach, studies 
have also revealed that tumors can acquire a resistance against 
this type of therapy, and the efficacy of adenoviral treatment 
still needs to be improved [13]. Since in vitro adenovirus 
serotype 5 (Ad5) infects cells via the CAR receptor, and 
CAR [14] and most of the hematologic cells do not express 
high levels of these receptors, Ad5 was not initially consid-
ered as a possible candidate for MM treatment. However, 
with recombinant technology, adenovirus can be redirected 
by modification of the viral attachment fiber knob [15], 
making its use in the treatment of hematological malig-
nancies possible. MM seems to be a better potential target 
for this therapy than solid tumors since it is easily accessible, 
with malignant cells found predominantly in the bone mar-
row and blood [10]. Several serotypes of adenovirus may 
be suitable as vectors for tumor therapies. Among the differ-
ent serotypes, Ad5 was the first to be used as a therapeutic 
alternative for MM in 2007 [16]. In order to investigate 
the ability of Ad5 to infect myeloma cells, Senac et al. studied 
the in vitro permissivity of 2 myeloma cell lines, ALMC-1 
and ALMC-2, derived from patient samples and representing 
2 different stages of disease [17]. Furthermore, by distinguish-
ing tumor cells positive for the expression of the CD138 
surface marker from normal bone marrow cells that lack 
CD138 expression, they confirmed that Ad5 infects a higher 
ratio of tumor cells in MM. Senac et al. proved that not 
only Ad5, but also Ad6, Ad26, and Ad48 are capable of 
infecting and killing the majority of MM cell lines as well 
as ex vivo primary cells from patients, confirming the feasi-
bility of translating adenovirus-based therapies to MM 
patients. Their data suggested that adenovirus may retain 
the ability to selectively kill tumor cells while sparing normal 
bone marrow cells in the context of MM treatment [18].
ADENOVIRUS AS A VECTOR FOR GENE THERAPY 
IN MULTIPLE MYELOMA
The second described strategy, taking advantage of the 
characteristics of adenovirus, is based on the insertion of 
genes of interest into the genome of a modified adenovirus. 
In this way, it is possible to use the modified viral particles 
for delivering genes that are, for example, defective or mu-
tated in the tumor [15], codifying for enzymes that can 
be then used to activate specific drugs [19], or codifying 
for proteins able to inhibit the tumor growth directly or 
indirectly by inducing an immune response [20], specifically 
to MM tumor cells.
An example of the first strategy (i.e., delivery of defective 
of mutated genes to the tumor) is found in the work of 
Torturro, who described adenovirus-mediated cytotoxic gene 
therapy, showing the efficiency of recombinant adenovirus- 
p53-mediated cytotoxicity in vitro in Burkitt's lymphoma 
and MM [15]. In their work, they emphasized the importance 
of CAR expression and cellular signaling pathways in ad-
enovirus-mediated cytotoxic therapies for MM and other 
lymphoproliferative malignancies [15]. Using a similar strat-
egy, Ni et al. were able to block proliferation in the MM 
cell line U266 by expressing the dominant negative inhibitor 
of κBα (Ad5IκB), blocking in this way the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) acti-
vation [21].
As an example of coding for enzymes that activate specific 
drugs, Teoh et al. studied the ability of adenoviral vectors 
to deliver the thymidine kinase (tk) gene into MM cells. 
This group demonstrated that MM cell lines and MM patient 
cells express both adenoviral receptors and DF3/MUC1 
protein. They hypothesized that the DF3 promoter could 
be used as a selective promoter to control the expression 
of therapeutic recombinant genes only in tumor cells [19]. 
In that study, expression of the tumor-selective promoter 
DF3/MUC1 was found only in MM-derived cells (MUC-pos-
itive) and was absent in hematopoietic progenitor cells 
(MUC1-negative) [19]. In a combinatory study, the ex-
pression of tk in MM potentiated in vivo killing by a combina-Korean J Hematol 2011;46:229-38.
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tion of viral therapy with ganciclovir [22].
An example of the third strategy is the work of Fernandes 
et al., who used a conditionally replicating adenovirus con-
taining the CD40 ligand transgene (AdEHCD40L) to demon-
strate growth inhibition in MM cells [20]. This strategy was 
based on previous findings that showed CD40L can directly 
modulate MM cell growth. Their work has effectively dem-
onstrated that the presence of CD40L is associated with viral 
oncolysis and results in MM growth inhibition by activating 
cellular apoptosis [23]. Considering these findings, the clin-
ical application of AdEHCD40L has been proposed in ex-
perimental MM treatments [20]. F u r t h e r m o r e ,  w i l d  t y p e  
genes for mutated oncogenes can be introduced. For example, 
Ren  et al. designed a vector combining p53 and im-
munomodulatory molecules, including the GM-CSF (cyto-
kine granulocyte macrophage colony-stimulating factor) and 
the costimulatory molecule B7-1 (Ad-p53/GM-CSF/B7-1). 
In 2005, they used this strategy to cotransfer those 3 mole-
cules into MM cell lines and primary myelomas, demonstrat-
ing the feasibility and increased immunogenicity of those 
treated MM cells [24].
OTHER POSSIBLE VIRUSES EXPLORED AS 
ALTERNATIVE CURES FOR MM
Since the majority of the population has encountered ad-
enovirus at some point in life, and therefore, a rapid humoral 
immune response versus the virus and the modified agent 
is generated, the field of viral therapy is also considering 
other viruses as alternatives for the treatment of MM. Among 
those, as comprehensively reported by Thirukkumaran and 
Morris, the VV was first used in 1980 as a virotherapeutic 
agent in a 67-year-old Japanese patient with IgA MM [25, 
26]. Consequently, intravenous injection of the vaccinia 
strain was found to result in a significant reduction in IgA 
levels. To date, other clinical trials testing different VV mu-
tants, such as JX-594, have been conducted in patients with 
metastatic liver cancer. This agent has been considered a 
possible candidate for clinical trials in hematological malig-
nancies, including MM [27]. Other clinical trials in MM 
have been performed using vesicular stomatitis virus (VSV) 
as oncolytic agent. Data from those trials suggests that genet-
ically engineered VSV strains such as VSVΔ51, which has 
been used in vivo, can be considered as components in poten-
tial combination therapies (e.g., with radiation treatment) 
for MM [28]. Combination therapy with radiation and viral 
therapy was reported to have good efficacy in a phase I/II 
clinical trial using reovirus (reolysin) [29-32]. Reovirus was 
found to be an attractive anticancer therapeutic in further 
clinical tests for hematological malignancies. Thirukkumaran 
and Morris anticipated that after encouraging preclinical 
data is obtained, reovirus will be used in clinical settings 
in the very near future [10]. Myers et al. reported new 
ongoing phase I clinical trials with MV for MM. This trial 
includes a combination of viral and conventional therapies, 
consisting of intravenous administration of MV-NIS (MV 
expressing the sodium-iodide symporter) used with or with-
out cyclophosphamide [33]. In this trial, patients are pre-
treated with cyclophosphamide 2  d a y s  p r i o r  t o  M V - N I S  
injection. Pretherapy and post-therapy hematological and 
biochemical parameters are yet to be determined, and an-
ti-measles immunity is being monitored. This study also 
includes serial imagining of virus biodistribution post-123I 
administration [34]. In unpublished data, Msaouel et al. [35] 
described encouraging results of this therapy in MM for 
future phase II/III clinical trials. The MV-Edm (Edmonston-B 
vaccine MV) strain has also been shown to have oncolytic 
activity against MM. In experiments employing a transplant 
model in immune-deficient mice, using different clinical 
MM samples, this agent successfully killed MM cells [36]. 
CVA21 is an another potential purging agent, with an ability 
to selectively target hematological malignant cells [37]. Its 
specificity is most likely related to the expression of both 
intracellular adhesion molecule-1 (ICAM-1) and decay accel-
erating factor (DAF) on the surface of target cells [38, 39]. 
This virus has already been administered to end-stage MM 
patients without adverse effects [40], but ongoing human 
trials are still necessary to evaluate the safety of this therapy.
POSSIBLE OBSTACLES TO VIRAL THERAPIES
Immunogenicity of adenovirus
The injection of adenovirus can lead to the activation 
of innate and adaptive immune responses against the virus 
itself. In fact, the strong immunogenicity of this virus is 
considered one of the major limitations for the in vivo use 
of this agent. Nayak and Herzog provided a comprehensive 
overview on the interactions between the immune system 
and adenoviral vectors [41], suggesting that immune re-
sponses against adenovirus can be directed either against 
the viral protein of the capsid, the vector backbone, or its 
genomic double-stranded DNA, as demonstrated in gene 
therapy trials testing the inserted gene.
Systemic delivery of adenovirus vectors results in rapid 
physiological responses that include activation of innate im-
munity, induction of cytokines, inflammation, transient liver 
toxicity, and thrombocytopenia [42]. The innate immune 
response, through activation of Toll-like receptor (TLR)-2 
and TLR-9, stimulates the production of type I interferons 
(IFNs), resulting in the production of inflammatory cytokines 
that promote Th1-type immunity with cellular and humoral 
immune responses [43, 44]. Natural killer (NK) cells are 
strongly activated by type I IFNs [45] and are known to 
be mediators of CD4 and CD8 responses. Adenovirus can 
also induce the innate immune response through MyD88/ 
TLR-dependent and/or MyD88/TLR-independent pathways 
in different cell types [46, 47]. Part of viral clearance is 
due to complement opsonization [44] and the generation 
of inflammation, especially in patients with pre-existing anti-
bodies against adenovirus. Rapid innate activation, as well 
as the subsequent cytokine storm (IL-6, type I IFNs, RANTES, 
IL-12 (p40), IL-5, G-CSF, and GM-CSF), stimulate and acti-Korean J Hematol 2011;46:229-38.
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vate the adaptive immune system [42]. Type I IFN signaling 
is important for the production of antibodies against ad-
enovirus, and neutralizing antibodies have been found to 
be effective in blocking innate and adaptive immune re-
sponses to the adenovirus.
The generation of humoral immune responses is crucial, 
since it precludes re-administration of the same serotype. 
Moreover, more than 97% of humans have pre-existing anti-
bodies against group C adenoviruses as a result of natural 
infection.
T cells directed against different serotypes have been found 
in humans. Adenovirus-specific CD4＋ T cells recognize con-
served epitopes among different serotypes, and it is possible 
to find these T cells as well pre-activated CD8 cells able 
to recognize adenoviral epitopes in the circulation of healthy 
donors. For these reasons, bypassing the immune response 
to adenovirus seems to be one of the major challenges in 
the optimization of this novel therapy. 
In order to overcome this limitation, several strategies 
have been utilized, from targeting specific organs, to en-
gineering viral envelopes, switching serotypes, or modifying 
the transgene cassette. Even immune modulation regimens 
associated with viral therapy can result in immune avoidance 
of the viral vector and transgene product, and in some cases, 
tolerance to the therapeutic gene product can be induced. 
For example, Mastrangeli et al. showed that the use of sub-
group D partially avoided the generation of neutralizing 
antibodies in a cystic fibrosis trial [48]. Despite the high 
immunogenicity of adenovirus vectors, which is generally 
considered a downside in the context of gene therapy, this 
could possibly prove to be advantageous when developing 
cancer vaccines since the adenovirus vector may serve as 
an optimum adjuvant [49].
IFN-STIMULATED GENES, VIRAL STRESS-INDUCED 
GENES AND THE PHYSIOLOGICAL RESPONSE 
TO VIRUSES
Viruses physiologically trigger an immediate antiviral in-
nate response that fights viral infection, replication, and 
spread. In fact, viral pathogens associated molecular patterns 
(PAMPs) are recognized by TLRs and are activated through 
IFN regulatory factor (IRF)-3, IRF-5, IRF-7, or NF-κB a 
transcription factor responsible for the regulation of hun-
dreds of viral stress-inducible genes (VSIGs) that code for 
proteins with antiviral functions. The TLRs specifically in-
volved in viral recognition are TLR2, TLR3, TLR4, TLR8, 
and TLR9 [50].
A similar antiviral status can also be induced in uninfected 
cells, through viral stress-related products originating from 
neighboring infected cells [51]. In fact, when a virus infects 
a cell, IFNs are synthesized and secreted as a first line of 
defense [52]. Transcriptional activation by IFN proteins bind-
ing to their specific cell surface receptors leads to the tran-
scription of IFN-stimulated genes (ISGs), whose products 
inhibit different stages of viral replication [52]. IFN genes 
encode for a large family of multifunctional, secreted, small 
regulatory glycoproteins that have important signaling roles 
in the innate immune response.
There are 3 main types of IFNs: Type I or ‘viral’ IFNs 
include IFN-α, IFN-β, IFN-ω, and IFN-τ; type II IFNs include 
IFN-γ; and type III IFNs, including IFN-λ, are still not well 
described and have been suggested to be ancestral type I 
IFNs that also regulate the viral response [53]. Considerable 
progress has been made in describing the physiological role 
of IFN signaling components and subsequent antiviral activ-
ities [47, 54].
Gene targeting studies have distinguished the 4 main effec-
tor pathways of the IFN-mediated antiviral response:
1) myxovirus (Mx) GTPase pathway;
2) 2´,5´-oligoadenylate-synthetase-directed ribonuclease 
L pathway;
3) protein kinase R pathway;
4) IFN stimulated gene 15 (ISG15) ubiquitin-like pathway.
These pathways block viral transcription, degrade viral 
RNA, inhibit translation, and modify protein function to 
control each replication step of most viruses [53]. The sets 
of VSIGs and ISGs that are usually upregulated by viral 
infection and type I or type II stimulation (Fig. 1) clearly 
overlap partially [55]. The activation of ISGs promotes the 
expression of proteins with direct antiviral functions, such 
as the Mx-resistance-A (MxA) protein that protects infected 
as well as noninfected bystander cells. MxA proteins are 
rapidly induced to high levels following IFN or viral exposure 
and have direct antiviral activity against a wide variety of 
viruses, including adenovirus [56, 57]. Fig. 1 summarizes 
the well-studied pathways known to induce upregulation 
of VSIGs and ISGs.
With the molecular characterization of the transcriptional 
profiles of many tumors, our group and others have reported 
the existence of 2 subgroups of cancer cells, distinguishable 
by a spontaneous activation of the ISG molecular profile 
independent from viral infection or the presence of IFNs 
in the microenvironment [58-62]. Analysis of this new ge-
nomic data has shown that histologically different cancer 
types, including pancreatic [58], breast, head and neck, pros-
tate, and lung cancer, as well as melanomas and gliomas, 
generate microarray profiles that identify 2 subgroups dis-
tinguishable by specific gene expression of IFNs and in-
flammatory chemokines [60-63]. In epithelial ovarian cancer, 
deregulation of JAK/STAT signaling was identified as a cause 
of discrimination at the molecular level the 2 different sub-
types of tumors characterized by the differential expression 
of ISGs [64]. Several reports have described some ISGs as 
markers in solid tumors, both in prognostic and diagnostic 
contexts. For example, in 2006, Andreu et al. showed that 
IFTM1, one of the most upregulated ISGs following viral 
infection, was found to be upregulated downstream of β-cat-
enin signal in colorectal tumors [65]. The same marker was 
found by Gyorffy et al. in ovarian carcinoma, where IFITM1 
was actually shown to be associated with therapeutic re-
sponses in all treatments analyzed [66]. Weichselbaum et 
al. proved that, in breast cancer, the VSIG signature is very Korean J Hematol 2011;46:229-38.
Novel viral therapy for multiple myeloma 233
Fig. 1. Different signaling pathways leading to the induction of virus stress-inducible genes (VSIGs) and interferon-stimulated genes (ISGs). Left:
virus binding to TLR, stimulating the TLR/MyD88 pathway and leading to the activation and release of NF-κB into nucleus. Center: the dsRNA 
signaling pathway requires TLR3; there are at least 3 different mechanisms of inducing VSIGs. Right: the JAK/STAT pathway is activated by IFNα,
-υ, -β, or -λ; the ISGF3 complex, consisting of STAT1, STAT2, and IRF9, is formed and translocates into nucleus, binding to the ISRE promoter 
sequence of different ISGs and components of the IFNγ pathway for the activation of GAS promoter sequences. IFNλ mediates the transcription 
of VSIGs and ISGs through initiation of ISREs or GASs. Abbreviations: TLR, Toll-like receptor; MyD88, myeloid differentiation primary response gene
88; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IFN, interferon; ISGF, interferon stimulated gamma factor; IRF, interferon
regulatory factor; ISRE, interferon stimulated response element; STAT, signal transducer and activator of transcription; GAS, interferon-activated site.
important for DNA damage resistance and therefore can 
be used as a predictive marker for chemotherapy and radia-
tion therapy [61].
While ISG overexpression in solid tumors has previously 
been described, and several reports have shown that the 
phenotype of the tumor is dependent on this profile, we 
were the first to associate this phenotype to an in vitro 
resistance to oncolytic and gene therapy approaches for pan-
creatic cancer [58] and recently for other types of cancers 
as well, including MM, ovarian cancer, melanoma, RCC, 
and colon carcinoma (Raus et al., manuscript in preparation). 
In fact, we showed that ISG-positive tumor cell lines do 
not allow either oncolysis or the expression of proteins deliv-
ered by adenovirus or adeno-associated virus [58].
In our specific study, we reported for the first time an 
intrinsic antiviral phenotype in tumor cells that appeared 
to be independent of the tumor microenvironment, and we 
performed transcriptional profiling of 3 chronic pancreatitis, 
3 primary pancreatic ductal adenocarcinoma (PDAC), 3 
paired noncancerous surrounding pancreatic tissues, and 8 
PDAC xenografts. We clearly identified 2 distinct PDAC 
cell phenotypes according to the expression of ISGs, and 
we found that among several ISGs, 2 phenotypes could be 
accurately identified by the downstream expression of MxA, 
which was strongly correlated with the activated antiviral 
phenotype. MxA, the mediator of one of the first antiviral 
mechanisms elucidated, is located at a critical intersection 
of the previously analyzed pathways and is shared by all 
of these pathways. Therefore, its expression is rapidly in-
duced to high levels when IFN or TLR signals occur [56, 
67]. We then expanded our analysis to test the level of 
MxA expression in 23 human PDACs and 10 human PDAC 
xenografts by tissue array immunohistochemistry, and we 
observed constitutive expression of MxA in about 50% of 
samples. This antiviral state is independent from the tumor 
microenvironment since it could be confirmed by an in 
vitro model of human tumors that demonstrated resistance 
to adenoviral replication and lysis [58]. Furthermore, we 
found that this status is independent from the presence of 
IFNs and is caused by spontaneous activation of IFN-stimu-Korean J Hematol 2011;46:229-38.
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lated response element (ISRE) sequences [58]. Recently, we 
published an in vivo study where we confirmed that the 
antiviral MxA-positive phenotype is acquired by ovarian 
cancer cells in vivo as an escape to oncolytic adenoviral 
pressure in a murine model [13]. We believe that the ob-
servation of this cancer antiviral phenotype might be of 
practical significance in stratifying patients as likely or un-
likely to respond to viral vector-delivered gene therapy; 
moreover, it might provide insights into the biology of a 
subset of human tumors. A thorough understanding of how 
this antiviral phenotype is generated and if this phenotype 
may become a new in vivo escape mechanism to viral-based 
therapies is important in improving the present clinical out-
comes of viral therapies.
CONCLUSIONS
Because of the limited efficacy of conventional therapies, 
new strategies in the treatment of MM are required. 
Numerous approaches to novel biological therapies are cur-
rently under investigation. Remarkable progress has been 
made in the field of gene therapy, and, thanks to its great 
potentiality, the techniques of gene transfer are continuously 
being improved, attracting increasing interest from 
clinicians. However, many obstacles still need to be over-
come, including improvement of transfection efficiencies, 
targeting to malignant cells, immune system humoral re-
sponse against the inoculated viral particles, possible tumor 
escape through upregulation of specific gene sets, and possible 
toxic viral side effects, which are under evaluation in several 
completed phase I trials. Human clinical trials using ad-
enovirus in MM patients have not yet been performed; how-
ever, determining the safety of these therapies in phase I 
and phase II trials will be the first step in translating oncolytic 
adenoviral therapy to MM patients. Although oncolytic vi-
rus-based therapies in MM are only beginning to realize 
their potential, they appear to be promising future treatments 
for this disease.
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Supplementary Table 1. Oncolytic adenoviral therapy trials in solid tumors.
Virus N Disease Phase Route Results References
Onyx-015 23 Pancreatic ca. I Direct inj. 6 TR, 11 SD Hammersmith Hospital, UK 
Onyx-015 21 Pancreatic ca. II Direct inj. 2 PTR, 2 MR, 6 SD Jonsson Comprehensive 
Cancer Center, LA, USA.
Onyx-015 21 Pancreatic ca. I/II Virus± 
gemcitabine
No objective response Sangro B, Mazzolini G, 
Ruiz J et al.
Onyx-015 30 H&N tumors II IT＋CTx 8 CR but long-term survival 
not improved
Ganly et al., 2000
Onyx-015 22 SCCHN I Inj. 3 PR, 2 MR, 8 SD Ganly et al., 2000
Onyx-015 30 SCCHN II Inj. 1 CR, 3 PR, 12 SD  Nemunaitis et al., 2001
Onyx-015 10 SCCHN II Inj. 1 CR, 4 SD Nemunaitis et al., 2001
Onyx-015 37 SCCHN II Inj. 8 CR, 11 PR, median survival 
10.5 months
Khuri et al., 2000
Onyx-015 16 Ovarian ca. I IT 0 P/CR Vasey et al., 2002
Onyx-015 5 Solid tumor I IV  0 P/CR Nemunaitis et al., 2003
Onyx-015 5 Colon ca. I IV  0 P/CR Nemunaitis et al., 2003
Onyx-015 5 Hepatocellular ca. I IV＋IT 1  PR Habib  et al., 2003
Onyx-015 9 Colon ca. I IHA  1 PR Reid et al., 2001
Onyx-015 10 Solid tumor I IV  0 P/CR, 8 SD Nemunaitis et al., 2001
Onyx-015 23 Pancreatic ca. I IT  0 P/CR, 6 MR, 10 SD Mulvihill et al., 2001
Onyx-015 27 GI ca. liver meta.  II IHA  3 PR, 4 MR, 9 SD Reid et al., 2002
Onyx-015 21 Pancreatic ca. I Inj. 2 PR, 2 MR, 6 SD Hecht et al., 2003
Onyx-015 18 Colon ca. II IV＋IT 7 SD Hmid et al., 2003
Onyx-015 20 Hepatabilliary II IT 1  PR Makower  et al., 2003
Ad-OC-TK 6 Prostate ca. I/II inj. 3 GR Shirakawa et al., 2007
Ad.IL12 21 GI tumor I IT Mild tumor effects Sangro B, Mazzolini G, Ruiz J
Ad.IL12 7 Pancreatic ca. I IT Mild tumor effects Sangro B, Mazzolini G, Ruiz J
Ad. vector 15 Melanoma, meta. I ex vivo/ s.c.  3 PR Schreiber S et al., 1999
Ad. vector 23 Melanoma, meta. I IT 7 LR Stewart AK et al., 1999
Ad. vector 12 Prostate ca. local. I IT＋surgery  Significant decrease of PSA levels 
in most patients
Trudel S et al., 2003
Ad. vector 21 NSCLC I IT NR Griscelli F et al., 2003
Ad. vector 21 NSCLC I IT Amelioration of time to disease 
progression
Roth JA et al., 1998
Ad. vector 24 NSCLC I IT＋CTx  2 PR, 17 SD, 4 PD, 1 NE Nemunaitis J et al., 2004
Ad. vector 15 NSCLC I IT  4 SD Schuler M et al., 1998
Ad. vector 25 NSCLC II IT＋CTx No significant benefit over 
CTx alone
Schuler M et al., 2001
Ad. vector 12 Bladder ca. I IT or 
intravesical＋
Instillation＋
cystectomy
Not evaluated Kuball J et al., 2001
Ad. vector 13 Bladder ca. I Intravesical 
instillation
2 SD, 11 PD Pagliaro LC et al., 2003
Ad. vector 36 Ovarian ca. I/II IP＋CTx >50% reduction of CA125 levels 
in 8; 10 long-term survivors after 
treatment with multiple doses
Buller RE et al., 2002; 
Pegram M et al., 2002
Ad. vector 27 NSCLC I IT  2 PR, SD in 16, 7 PD Swisher SG et al., 1999
Ad. vector 19 NSCLC II IT＋RTx 1 CR, 11 PR, 3 SD, 2 PD, 2 NE Swisher SG et al., 2003
Ad. vector 15 Glioma I IT＋surgery Mean progression-free survival 
13 wk, median overall survival 43 wk
Lang FF et al., 2003
Ad. vector 15 Ovarian ca. I IP 5 SD, 8 PD Alvarez RD et al., 2000
Ad. vector 13 Glioblastoma I IT 3 SD Trask TW et al., 2000
Ad. vector 14 Glioblastoma I/II IT 1 CR, 5 PR, 4 SD, 4 PD Sandmair AM et al., 2000
Ad. vector 14 Glioblastoma I IT＋surgery No clinical response Smitt PS et al., 2003
Abbreviations: CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PD, progressive disease; H&N, head and
neck; SCCHN, squamous cell carcinoma of the head and neck; NSCLC, non-small-cell lung cancer; HCC, hepatocellular cancer; Ad., 
Adenoviral; CTx, chemotherapy; RTx, radiotherapy; TR, tumor regression; PTR, partial tumor regression; GR, good response; LR, local 
response; PSA, prostate specific antigen; ATAP, Advanced Therapy Access Program; inj., injection; IT, intratumoral; IV, intravenous; IP, 
intraperitoneal; IHA, intrahepatic artery.Korean J Hematol 2011;46:229-38.
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Supplementary Table 1. Continued.
Virus N Disease Phase Route Results References
Ad. vector 18 Prostate ca. I IT PSA response in 1 Herman JR et al., 1999
Ad. vector 30 Prostate ca. I/II IT＋RTx Not reported Teh BS et al., 2001
Ad. vector 11 Prostate ca. I IT 1 SD Kubo H et al., 2003
Ad. vector 22 H&N ca. I IT 3 PR Ganly I et al., 2000
Ad. vector 3 HCC I IT Not reported Habib NA et al., 2001
Ad. vector 6 Colon ca. 
liver meta.
I IHA or IV Not reported Habib NA et al., 2001
Ad. vector 7 Liver meta. from 
colon ca. or 
unknown primary
II IHA＋CTx 6 SD, 1 PD Habib NA et al., 2001
Ad. vector 5 HCC II IV＋IT  1 PR, 4 PD  Habib NA et al., 2002
Ad. vector 23 Pancreatic ca. I IT 6 MR, 10 SD Mulvihill S et al., 2001
Ad. vector 10 Meta. solid tumors I IT＋CTx  1 MR, 8 SD Nemunaitis J et al., 2001
Ad. vector 16 Ovarian ca. I IP 4 SD Vasey PA et al., 2002
Ad. vector 21 Pancreatic ca. I/II IT＋CTx 2 PR, 2 MR, 6 SD, 11 PD Hecht JR et al., 2003
Ad. vector 37 H&N ca. II IT＋CTx 8 CR, 1 PR Khuri FR et al., 2000
Ad. vector 40 H&N ca. II IT  3 CR, 2 PR, 3 MR, 13 SD, 15 PD Nemunaitis J et al., 2001
Ad. vector 27 GI ca. liver meta.  II IHA＋CTx 3 PR, 4 moderate response 
(including 3 CTx resistant tumors), 
9 SD, 11PD
Reid T et al., 2002
Ad. vector 20 Prostate ca. I IT Reduction in serum PSA in 13 
(including 4 PR)
DeWeese TL et al., 2001
Ad. vector 16 Prostate ca. I IT 7 MR, 3 PR Freytag SO et al., 2002
Ad5-Δ24-
RGD
21 Ovarian ca. I IP 14 SD, 5 PD, 0 P/CR Kimball KJ et al., 2010
CG7870 23 Hormone 
refractory
I IV 5 declain in PSA Small EJ et al., 2006
Ad5-D24-
RGD
8 Advanced solid 
tumors
ATAP IT＋IV 3 showed progress Pesonen S et al., 2010
Ad5/3-
Cox2L-D24
14 Advanced solid 
tumors
ATAP IT＋IV 10 showed progress Hemminki A et al., 2010
H103 
 
27 Advanced solid 
tumors
I IT 13 (PR/MR/SD) Li JL et al.
KH901 19 H&N ca. I IT 12 SD Chang J et al., 2009
Ad5/3-D24-
GMCSF
12 Advanced solid 
tumors
ATAP IT＋IV 8 (MR/SD) Koski A et al., 2010
Ad5-D24-
GMCSF
16 Advanced solid 
tumors
ATAP IT＋IV 8 (CR/MR/SD) Cerullo V et al., 2010
Abbreviations: CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PD, progressive disease; H&N, head and
neck; SCCHN, squamous cell carcinoma of the head and neck; NSCLC, non-small-cell lung cancer; HCC, hepatocellular cancer; Ad., 
Adenoviral; CTx, chemotherapy; RTx, radiotherapy; TR, tumor regression; PTR, partial tumor regression; GR, good response; LR, local 
response; PSA, prostate specific antigen; ATAP, Advanced Therapy Access Program; inj., injection; IT, intratumoral; IV, intravenous; IP, 
intraperitoneal; IHA, intrahepatic artery.